TissueTech, Inc., a Miami, Florida-based developer of regenerative tissue engineering solutions, completed a $10m growth equity financing.
Backers included River Cities Capital Funds and Ballast Point Ventures. In conjunction with the investment, River Cities’ Carter McNabb, and Ballast Point Ventures’ Matt Rice will join TissueTech’s Board of Directors.
Founded in 2001 by Amy Tseng, President and CEO, and Scheffer Tseng, MD, PhD, Chairman and Chief Scientific Officer, TissueTech provvides regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The company offers a portfolio of amniotic membrane and umbilical cord-based tissue and device products through two commercial entities:
– BioTissue, Inc., a provider of regenerative tissue therapies for ocular surface diseases and disorders, and
– Amniox Medical, a technology provider to the musculoskeletal and wound care markets.
It intends to use the funds to accelerate commercial efforts and further research and development in both divisions.